22 results
Keyword Alemtuzumab Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Lemtrada (updated)
alemtuzumab, Multiple Sclerosis
Date of authorisation: 11/09/2013, Revision: 6, Authorised -
List item
Human medicine European public assessment report (EPAR): MabCampath
alemtuzumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 06/07/2001, Revision: 14, Withdrawn -
List item
Human medicine European public assessment report (EPAR): Arzerra
ofatumumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 18/04/2010, Revision: 16, Authorised -
List item
Human medicine European public assessment report (EPAR): Tysabri
natalizumab, Multiple Sclerosis
Date of authorisation: 26/06/2006, Additional monitoring, Revision: 27, Authorised -
List item
Human medicine European public assessment report (EPAR): Gilenya
fingolimod, Multiple Sclerosis
Date of authorisation: 16/03/2011, Additional monitoring, Revision: 20, Authorised -
List item
Human medicine European public assessment report (EPAR): Mavenclad
cladribine, Multiple Sclerosis
Date of authorisation: 21/08/2017, Revision: 2, Authorised -
List item
Human medicine European public assessment report (EPAR): Ocrevus
ocrelizumab, Multiple Sclerosis
Date of authorisation: 07/01/2018, Additional monitoring, Revision: 2, Authorised -
List item
Human medicine European public assessment report (EPAR): Prevymis
letermovir, Cytomegalovirus Infections
Date of authorisation: 07/01/2018, Additional monitoring, Revision: 1, Authorised -
List item
Human medicine European public assessment report (EPAR): Imbruvica
ibrutinib, Lymphoma, Mantle-Cell Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 20/10/2014, Additional monitoring, Revision: 12, Authorised -
List item
Human medicine European public assessment report (EPAR): Folotyn
pralatrexate, Lymphoma, T-Cell
Date of refusal: 20/06/2012, Refused -
List item
Human medicine European public assessment report (EPAR): Zessly (updated)
infliximab, Arthritis, Psoriatic Psoriasis Crohn Disease Arthritis, Rheumatoid Colitis, Ulcerative Spondylitis, Ankylosing
Date of authorisation: 18/05/2018, Additional monitoring, Biosimilar, Revision: 1, Authorised -
List item
Human medicine European public assessment report (EPAR): Plegridy
peginterferon beta-1a, Multiple Sclerosis
Date of authorisation: 17/07/2014, Additional monitoring, Revision: 14, Authorised -
List item
Human medicine European public assessment report (EPAR): Torisel
temsirolimus, Carcinoma, Renal Cell Lymphoma, Mantle-Cell
Date of authorisation: 18/11/2007, Revision: 28, Authorised -
List item
Human medicine European public assessment report (EPAR): Zinbryta
daclizumab, Multiple Sclerosis
Date of authorisation: 30/06/2016, Additional monitoring, Revision: 8, Withdrawn -
List item
Human medicine European public assessment report (EPAR): Erelzi
etanercept, Arthritis, Psoriatic Psoriasis Arthritis, Juvenile Rheumatoid Arthritis, Rheumatoid Spondylitis, Ankylosing
Date of authorisation: 22/06/2017, Additional monitoring, Biosimilar, Revision: 3, Authorised -
List item
Human medicine European public assessment report (EPAR): Istodax
romidepsin, Lymphoma, Non-Hodgkin
Date of refusal: 11/02/2013, Refused -
List item
Human medicine European public assessment report (EPAR): Venclyxto (updated)
venetoclax, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 04/12/2016, Additional monitoring, Conditional approval, Revision: 6, Authorised -
List item
Human medicine European public assessment report (EPAR): Gazyvaro
obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 22/07/2014, Additional monitoring, Revision: 6, Authorised -
List item
Human medicine European public assessment report (EPAR): Zydelig
idelalisib, Lymphoma, Non-Hodgkin Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 17/09/2014, Additional monitoring, Revision: 14, Authorised -
List item
Human medicine European public assessment report (EPAR): Revolade
eltrombopag, Purpura, Thrombocytopenic, Idiopathic
Date of authorisation: 10/03/2010, Revision: 21, Authorised -
List item
Human medicine European public assessment report (EPAR): Cosentyx (updated)
secukinumab, Arthritis, Psoriatic Psoriasis Spondylitis, Ankylosing
Date of authorisation: 14/01/2015, Additional monitoring, Revision: 11, Authorised -
List item
Human medicine European public assessment report (EPAR): Nerventra
laquinimod, Multiple Sclerosis
Date of refusal: 18/08/2014, Refused